<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349800</url>
  </required_header>
  <id_info>
    <org_study_id>KVD900-101</org_study_id>
    <nct_id>NCT04349800</nct_id>
  </id_info>
  <brief_title>A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of KVD900 Followed by Crossover Sub-studies of KVD900 Formulations, and Food Effect in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KalVista Pharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KalVista Pharmaceuticals, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety, tolerability, pharmacokinetic and food effect study of KVD900 in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2018</start_date>
  <completion_date type="Actual">September 10, 2018</completion_date>
  <primary_completion_date type="Actual">September 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with Adverse Events</measure>
    <time_frame>Change from pre-dose to last visit, 5-7 days post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with Serious Adverse Events</measure>
    <time_frame>Change from pre-dose to last visit, 5-7 days post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory assessments</measure>
    <time_frame>Throughout study until last visit, 5-7 days post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs</measure>
    <time_frame>Throughout study until last visit, 5-7 days post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in electrocardiogram (ECG) measurements</measure>
    <time_frame>Throughout study until last visit, 5-7 days post dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>Derived from time-concentration plasma levels of KVD900</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-t</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>Derived from time-concentration plasma levels of KVD900</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-24</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>Derived from time-concentration plasma levels of KVD900</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-inf</measure>
    <time_frame>Up to 48 hours post dose</time_frame>
    <description>Derived from time-concentration plasma levels of KVD900</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - food effect (Part C only)</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>90% confidence intervals of the ratios for AUC0-t and Cmax with and without food lie in the range 80-125</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - formulation bridge - relative bioavailability (Part B only)</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>90% confidence intervals of the ratios for AUC0-t and Cmax between the two dosages lie in the range 80-125</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose - 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose - 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose - 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose - 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose - 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose - 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose - 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose - 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation Screen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KVD900</intervention_name>
    <description>Active</description>
    <arm_group_label>Food Effect</arm_group_label>
    <arm_group_label>Formulation Screen</arm_group_label>
    <arm_group_label>Single Ascending Dose - 10 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 160 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 20 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 300 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 40 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 5 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 600 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to KVD900</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Single Ascending Dose - 10 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 160 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 20 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 300 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 40 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 5 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 600 mg</arm_group_label>
    <arm_group_label>Single Ascending Dose - 80 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between 18 and 55 years of age.

          -  Healthy subjects as determined by past medical history and as judged by the Chief
             Investigator or designee.

          -  Male subject willing to use a highly effective method of contraception.

          -  Subject with a body mass index (BMI) of 18-32 kg/m2.

          -  Subject with no clinically significant history of previous allergy or sensitivity to
             KVD900 or any of the excipients contained within the investigational medicinal product
             (IMP).

          -  Subject with no clinically significant abnormal serum biochemistry, haematology,
             clotting profiles, and urine examination values within 28 days before the first dose
             of IMP.

          -  Subject with a negative urinary drugs of abuse screen, determined within 28 days
             before the first dose of IMP

          -  Subject with negative human immunodeficiency virus (HIV) and hepatitis B surface
             antigen (Hep B) and hepatitis C virus antibody (Hep C) results.

          -  Subject with no clinically significant abnormalities in 12-lead electrocardiogram

          -  Subjects must not donate sperm from first dose until at least 3 months after last dose
             of IMP.

          -  Subjects without any special food restrictions that would hinder ability to consume
             the high fat breakfast provided during study Part C; such as lactose intolerance ,
             vegan, low-fat, low sodium, etc.

          -  Subjects with no known allergy or sensitivity to lactose and/or any additional
             excipients contained in IMP.

          -  Subject must be available to complete the study (including all follow up visits).

          -  Subject must satisfy the Chief Investigator or designee about their fitness to
             participate in the study.

          -  Subject must provide written informed consent to participate in the study.

        Exclusion Criteria:

          -  A clinically significant history of gastrointestinal disorder likely to influence IMP
             absorption.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements .

          -  Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular (no
             history of syncope or vasovagal events), or metabolic dysfunction.

          -  Subjects with a history of clotting abnormalities.

          -  A clinically significant history of drug or alcohol abuse in the last 5 years.

          -  Users of nicotine products i.e., current smokers or ex-smokers who have smoked within
             the 6 months prior to dosing with the study medication or users of cigarette
             replacements.

          -  Inability to communicate well with Investigators.

          -  Participation in a New Chemical Entity clinical study within the previous 3 months or
             a marketed drug clinical study within the 30 days before the first dose of IMP.

          -  Donation of 450 mL or more blood within the 3 months before the first dose of IMP.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Wales</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

